초록 열기/닫기 버튼
목적: 단안약시에서 가림치료 종료 후 장기적인 시기능을 알아보고자 하였다. 대상과 방법: 성공적인 가림치료(유지요법 포함) 종료 후 1년 이상 경과관찰이 가능했던 단안약시 환자 70명을 후향적으로 조사하였다. 약시치료 성공 후에도 정상안의 시력발달이 완성될 때까지 유지요법 또는 관찰하였다. 최종관찰 시 정상안에 비해 LogMAR시력 두 줄 이상의 약시안 시력저하가 있는 경우 약시 재발로 정의하였다. 결과: 사시 19명, 굴절부등 33명, 혼합형 18명이었고, 가림치료 종료 및 최종관찰 시 평균 연령은 각각 7.7 ± 1.9세, 11.4 ± 2.9세이었다. 가림치료 종료 시 약시안 시력(LogMAR)은 평균 0.01 ± 0.03, 입체시는 평균 101.7 ± 87.5초각으로 최종관찰 시 모두 증진되었으나, 약시안의 시력 증진은 유의하지 않았다(p=0.21). 유지요법기간은 25.6±21.0개월로 약시치료 성공까지 기간의 3배였다. 최종관찰 시 약시 재발은 없었으며, 3명(4.3%)에서 정상안에 비해 한 줄의 약시안 시력저하를 보였다. 결론: 가림치료를 성공적으로 종료할 수 있었던 단안약시 환자들에서는 시간이 흐른 후에도 약시 재발 없이 정상 시기능이 유지되었다.
Purpose: To evaluate a long-term visual outcome following cessation of occlusion therapy in unilateral amblyopia. Methods: A total of 70 patients who successfully finished occlusion therapy (including maintenance therapy) for unilateral amblyopia and were followed up for at least 1 year after cessation of occlusion were retrospectively reviewed. Even after the success of occlusion therapy, maintenance therapy or regular examinations were performed until the visual development of the normal fellow eye (NE) was completed. The recurrence of amblyopia was defined as a 2 or more logarithm of the minimum angle of resolution (LogMAR) levels of visual acuity (VA) reduction of the amblyopic eye (AE), as compared to the NE, at the last evaluation. Results: Amblyopia was associated with strabismus in 19 patients, anisometropia in 33 patients, and both in 39 patients. The mean age at the cessation of occlusion and at the last evaluation was 7.7 ± 1.9 years and 11.4 ± 2.9 years, respectively. The mean VA of the AE was 0.01 ± 0.03 and mean stereopsis was 101.7 ± 87.5 seconds of arc at the cessation of occlusion, and both improved at the last evaluation. However, the improvement of mean VA of the AE was not statistically significant (p = 0.21). The mean duration of maintenance therapy was 25.6 ± 21.0 months, and was 3 times longer than the duration required to achieve success in the treatment of amblyopia. At the last evaluation, the recurrence of amblyopia was not found, while 3 patients (4.3%) lost 1 LogMAR level of VA in the AE, as compared to the NE. Conclusions: Visual outcome following successful cessation of occlusion therapy for unilateral amblyopia was favorable without recurrence of amblyopia.
